Multiple-dose study to examine safety, tolerability, pharmacokinetics, and pharmacodynamics of LY2148568 long-acting release in Japanese patients with type 2 diabetes mellitus.
Latest Information Update: 11 Apr 2018
At a glance
- Drugs Exenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Apr 2018 Results of pooled post hoc analysis of this and other ten trials assessing the relationship of heart rate changes with baseline heart rate and identifying patient characteristics associated with changes in heart rate in the Exenatide QW development program published in the Diabetes Therapy
- 16 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Aug 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.